| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
* Divisions of Rheumatology and
Hypertension and Nephrology, University of Colorado Health, Sciences Center, Denver, CO 80262; and
CBR Institute for Biomedical Research and Department of Pediatrics, Harvard Medical School, Boston, MA 02115
Activation of each complement initiation pathway (classical, alternative, and lectin) can lead to the generation of bioactive fragments with resulting inflammation in target organs. The objective of the current study was to determine the role of specific complement activation pathways in the pathogenesis of experimental anti-type II collagen mAb-passive transfer arthritis. C57BL/6 mice were used that were genetically deficient in either the alternative pathway protein factor B (Bf–/–) or in the classical pathway component C4 (C4–/–). Clinical disease activity was markedly decreased in Bf–/– compared with wild-type (WT) mice (0.5 ± 0.22 (n = 6) in Bf–/– vs 8.83 ± 0.41 (n = 6) in WT mice (p < 0.0001)). Disease activity scores were not different between C4–/– and WT mice. Analyses of joints showed that C3 deposition, inflammation, pannus, cartilage, and bone damage scores were all significantly less in Bf–/– as compared with WT mice. There were significant decreases in mRNA levels of C3, C4, CR2, CR3, C3aR, and C5aR in the knees of Bf–/– as compared with C4–/– and WT mice with arthritis; mRNA levels for complement regulatory proteins did not differ between the three strains. These results indicate that the alternative pathway is absolutely required for the induction of arthritis following injection of anti-collagen Abs. The mechanisms by which these target organ-specific mAbs bypass the requirements for engagement of the classical pathway remain to be defined but do not appear to involve a lack of alternative pathway regulatory proteins.
This article has been cited by other articles:
|
|
 |
|
  T. E. Morrison, J. D. Simmons, and M. T. Heise Complement Receptor 3 Promotes Severe Ross River Virus-Induced Disease J. Virol., November 15, 2008; 82(22): 11263 - 11272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Song, F. Qiao, C. Atkinson, V. M. Holers, and S. Tomlinson A Complement C3 Inhibitor Specifically Targeted to Sites of Complement Activation Effectively Ameliorates Collagen-Induced Arthritis in DBA/1J Mice J. Immunol., December 1, 2007; 179(11): 7860 - 7867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. K. Banda, K. Takahashi, A. K. Wood, V. M. Holers, and W. P. Arend Pathogenic Complement Activation in Collagen Antibody- Induced Arthritis in Mice Requires Amplification by the Alternative Pathway J. Immunol., September 15, 2007; 179(6): 4101 - 4109. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Katschke Jr., K. Y. Helmy, M. Steffek, H. Xi, J. Yin, W. P. Lee, P. Gribling, K. H. Barck, R. A.D. Carano, R. E. Taylor, et al. A novel inhibitor of the alternative pathway of complement reverses inflammation and bone destruction in experimental arthritis J. Exp. Med., June 11, 2007; 204(6): 1319 - 1325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mihai, M. T. Chiriac, K. Takahashi, J. M. Thurman, V. M. Holers, D. Zillikens, M. Botto, and C. Sitaru The Alternative Pathway of Complement Activation Is Critical for Blister Induction in Experimental Epidermolysis Bullosa Acquisita J. Immunol., May 15, 2007; 178(10): 6514 - 6521. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
